ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
34 announcements
Suven Life Sciences reached a 76% enrollment milestone for its Phase 3 Alzheimer's trial. Data readout is expected by April 2027, marking significant clinical progress.
Suven Life Sciences Ltd has scheduled a board meeting on May 13, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window remains closed until May 15, 2026.
Suven Life Sciences Ltd clarified to the BSE and NSE that there is no undisclosed material information affecting recent price and volume behavior. The company attributes the recent movement in its security to market speculation. All significant information under Regulation 30 of SEBI LODR has been previously disclosed.
Suven Life Sciences Limited submitted the Regulation 74(5) certificate for the quarter ended March 31, 2026. Issued by KFin Technologies, the certificate confirms compliance regarding the dematerialization and rematerialization of securities. This is a routine quarterly regulatory filing with no material impact on business operations.